Targetted CML treatments

Sally-Anne Heasman, Matthew Small, David MacEwan

Research output: Contribution to journalArticlepeer-review


The introduction of the tyrosine kinase inhibitor (TKI), imatinib, has had a significant impact in improving the long term survival prospects of patients with chronic myeloid leukaemia (CML). However, many patients develop resistance to imatinib, which has prompted the development of more potent TKIs and other new agents with different mechanisms of action. This article examines how TKIs work in CML, describes mutations that may develop to confer resistance and discusses
Original languageEnglish
Pages (from-to)11-15
Number of pages5
JournalBritish Oncology Pharmacy Association Bulletin
Publication statusPublished - 2011

Cite this